Background-The frequency, predictors, and consequences of stent thrombosis (ST) in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) have been incompletely studied. We sought to investigate the incidence, predictors, and clinical implications of ST occurring within 1 year after percutaneous coronary intervention in patients with NSTE-ACS.
C oronary stents significantly improve clinical outcomes in patients undergoing percutaneous coronary intervention (PCI). 1 Stent thrombosis (ST) remains a major limitation of stent implantation, resulting in high rates of morbidity and mortality. 2, 3 Although the risk of ST may be increased in patients with acute coronary syndromes (ACS) due to increased platelet activation, thrombin generation, and inflammation, 4 ST has predominantly been investigated in patients with stable ischemic heart disease. 3, 5, 6 Therefore, although the incidence, independent predictors, and clinical correlates of ST in patients with stable ischemic heart disease have been extensively studied, 3, [5] [6] [7] [8] less is known about ST in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS). 9 Drug-eluting stents (DES) result in delayed endothelial healing, 10 and concern has been expressed from retrospective necropsy observations that DES implantation in ruptured fibroatheromas will result in higher rates of late ST in patients with ACS. 11 Whether this is true in a prospectively studied clinical cohort with ACS has never been evaluated.
We have recently described the 30-day incidence, predictors, and clinical consequences of ST in patients with NSTE-ACS enrolled in the large-scale, multicenter, prospective, randomized, Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) trial. 12 In the present study, we extend our observations to 1-year follow-up and analyze the differences between early and late ST.
WHAT IS KNOWN
• Predictors and clinical correlates of stent thrombosis have been investigated mainly in patients with stable coronary artery disease. • There are scant data on the incidence, predictors, and outcomes of stent thrombosis in patients with non-ST-segment elevation acute coronary syndromes.
WHAT THE STUDY ADDS
• The present report is the largest study to date to investigate early and late stent thrombosis in patients with moderate and high-risk non-ST-segment elevation acute coronary syndromes. • Compared with elective stent implantation, stent thrombosis occurs with increased frequency in the first year after stent implantation in patients with non-ST-segment elevation acute coronary syndromes, especially within the first 30 days. • Insulin-treated diabetes mellitus, the number of diseased vessels, and dynamic ST-segment changes were independent predictors of stent thrombosis.
Methods

Study Protocol
The study design of the ACUITY trial has previously been reported in detail. 13 Briefly, ACUITY was a multicenter, prospective, randomized trial in patients with moderate-and high-risk NSTE-ACS in whom an early invasive strategy was intended. Patients were randomly assigned to heparin (unfractionated or enoxaparin) plus a glycoprotein IIb/IIIa inhibitor (GPI; abciximab or eptifibatide), bivalirudin plus a GPI, or bivalirudin monotherapy (with provisional GPI use allowed for refractory thrombotic complications) before coronary angiography. Immediately after the first random assignment, patients assigned to heparin plus a GPI or bivalirudin plus a GPI underwent a second random assignment to routine up-front treatment with a GPI or to deferred selective treatment with a GPI in those undergoing PCI. Angiography was performed in all patients within 72 hours of random assignment. In patients treated with PCI, the choice of bare metal stents (BMS) or DES was at operator discretion. Dual antiplatelet therapy with aspirin and clopidogrel was strongly recommended for at least 1 year. All major adverse events observed during the study were adjudicated by an independent clinical events committee blinded to treatment assignment. Quantitative coronary angiography (QCA) was performed as previously described 12 at an independent angiographic laboratory (the Cardiovascular Research Foundation, New York, NY) as part of a formal substudy in 6921 patients enrolled in ACUITY, including 3405 patients in whom one or more stents were implanted. The study protocol was approved by the institutional review board or ethics committee at each center, and written informed consent was obtained from all patients. The authors had full access to the data and take full responsibility for their integrity. All authors have read and agree to the manuscript as written.
Objectives and Definitions
The primary objective of this study was to evaluate the incidence, predictors, and clinical correlates of 1-year ST. As per protocol, definite ST was defined as angiographic thrombus or total occlusion within the stented vessel at the time of clinically driven angiography for ischemia. Probable ST was defined as any death not attributed to a noncardiac cause or any Q-wave myocardial infarction (MI) in the target-vessel territory in the absence of documented angiographic stent patency. This definition is slightly different from the Academic Research Consortium definition of probable ST, 7 which includes any acute MI involving the target-vessel territory without angiographic confirmation. The extent of coronary artery disease per patient was defined as the sum of the lengths of lesions with Ͼ30% diameter stenosis by QCA. The Duke Jeopardy score has been previously described. 14
Statistical Analysis
Categorical variables were compared by 2 or Fisher exact test. Continuous data are presented as meanϮstandard deviation and were compared using the Student t test. All outcomes were expressed using Kaplan-Meier methodology and compared using the log-rank test. To identify predictors of ST, logistic multivariable analyses were performed by stepwise variable selection with entry and exit criteria set at Pϭ0.1. Multivariable analyses were performed both in the entire group of stented patients (nϭ7162) and in the prespecified cohort included in the QCA substudy (nϭ3405) to allow consideration of angiographic variables in the multivariable models. In the whole cohort of patients, multivariable analyses were performed using patient-level data both for definite/probable ST and for definite ST. In the subgroup of patients included in the formal angiographic substudy, logistic multivariable analyses were performed on definite ST, using patient and lesion-level data as previously specified. 12 The variables finally included in the multivariable models are specified in online-only Data Supplement Table I . Use of DES versus BMS was forced in each model. Statistical analyses were performed using SAS version 9.1. Probability values Ͻ0.05 were considered statistically significant.
Results
Incidence of ST at 1-Year Follow-Up
Among the 13 819 patients enrolled in the ACUITY trial, 7162 received at least 1 stent, constituting the present study cohort. At 1-year follow-up, there were 146 episodes of definite/probable ST (Kaplan-Meier estimated rate, 2.2%), 94 of which were definite (1.4%) and 52 of which were probable ST (0.8%). The incidence of early definite/probable ST (within 30 days) was 1.4% (100 episodes, 57 of which were definite and 43 probable), whereas that of late ST (30 days to 1 year) was 0.8% (46 episodes, 37 of which were definite and 9 probable). Similar rates of ST were observed among the 3405 patients included in the formal angiographic substudy; at 1-year follow-up, there were 69 episodes of definite/ probable ST (2.0%), 47 of which were definite (1.4%) and 22 probable (0.6%). The incidence of early definite/probable ST was 1.4% (49 episodes, 32 of which were definite and 17 probable ST), whereas that of late ST was 0.6% (20 episodes, 15 of which were definite and 5 probable ST). (Table 1) . Time from ST to major adverse events is shown in Figure 1A through 1F.
Implications of ST
As shown in
Predictors of 1-Year ST
Clinical, angiographic, and procedural characteristics of patients stratified according to the occurrence of ST are shown in Table 2 . The occurrence of early, late, or cumulative definite/probable and definite ST were similar in patients treated with DES and BMS ( Figure 2 ). Specifically, there were 89 and 57 episodes of 1-year definite/probable ST among the 4633 patients and the 2529 patients who received at least 1 DES and BMS, respectively (2.2% versus 2.3%, HR [95% CI], 0.86 [0.62-1.20], Pϭ0.38). Similarly, the rates of early, late and cumulative 1-year definite/probable ST and definite ST were not significantly different in patients randomly assigned to heparinϩGPI, bivalirudin plus a GPI, or bivalirudin alone ( Figure 3 ). By multivariable analysis, insulin-treated diabetes mellitus, the number of diseased vessels, and ST-segment deviation Ն1 mm were independent predictors of definite/probable ST at 30 days and of cumulative ST through 1 year, whereas insulin-treated diabetes was the only independent predictor of late definite/probable ST (online-only Data Supplement Table I ). Greater baseline When angiographic variables were added to the model, patients with 1-year ST compared with those without 1-year ST had a greater number of angiographic lesions, a greater number of diseased vessels, and a greater extent of coronary artery disease (online-only Data Supplement Table II ). Lesions with 1-year ST were also more likely to have coronary thrombus, abrupt closure during the procedure, no reflow, and Supplement Tables III and IV) . By multivariable analysis restricted to the cohort of patients in the angiographic substudy (nϭ3405), the extent of coronary disease per patient was the only independent predictor of cumulative 1-year definite ST (online-only Data Supplement Table I) ; insulin-treated diabetes approached statistical significance in this model (Pϭ0.0504).
Discussion
The present report is the largest study to date to investigate the incidence, predictors, and clinical correlates of 1-year ST in patients with moderate-and high-risk NSTE-ACS treated with either DES or BMS. The principal findings of this study are (1) ST in patients with moderate-and high-risk NSTE-ACS was relatively common, with 1.4% and 2.2% of patients having definite and definite/probable ST at 1 year follow-up, respectively; (2) both early and late ST were associated with a marked increase in all-cause mortality, cardiac mortality, MI, and TVR; (3) the most important predictors of ST within 1 year in NSTE-ACS were insulin-treated diabetes, STsegment deviation Ն1 mm, the number of diseased vessels, and the angiographic extent of coronary artery disease; and (4) in this large study, the rates of early, late, and cumulative 1-year ST in NSTE-ACS was not affected by the type of stent implanted (BMS versus DES), nor by the procedural antithrombotic regimen used.
Most trials in patients with stable ischemic heart disease have reported 30-day and 1-year definite/probable ST rates of Ͻ0.6% and Ͻ1%, respectively. 15, 16 In contrast, the early, late, and cumulative 1-year rates of ST observed among patients with NSTE-ACS in the present study were substantially higher. Increased platelet aggregation, 17 activation of the coagulation system, 18 heightened inflammatory responses, 19 and stent implantation in ruptured fibroatheromas with thrombus 11 may contribute to the higher risk of ST in patients with NSTE-ACS compared with stable coronary artery disease. Conversely, ST rates as high as 3% at 1 year have been reported in ST-segment elevation-MI, 20 -22 suggesting a gradient of ST risk ranging from lowest in stable coronary artery disease, intermediate in NSTE-ACS, and highest in STsegment elevation-MI.
The present report emphasizes the dire prognosis of patients with ST in NSTE-ACS, regardless of whether it occurs before or after 30 days. In contrast, Krukeya et al suggested that the clinical sequelae after ST may be less pronounced in patients with NSTE-ACS than in stable patients and that mortality in ACS may not be increased in patients developing ST after 30 days. 9 The results from our larger study emphasizes that ST in NSTE-ACS is associated with a very poor prognosis, with markedly increased rates of death, MI, and TVR, regardless of its timing. Earlier studies examining the predictors of ST have reported inconsistent results. In prior large series (most of which were retrospective, and in which most patients had stable ischemic heart disease), diabetes, renal dysfunction, premature discontinuation of dual antiplatelet therapy, reduced left ventricular ejection fraction, multiple stents, stent underexpansion, and stent length have been reported as correlates of ST. 3, [5] [6] [7] [8] 23, 24 In a study of 8146 patients recruited at 2 academic hospitals in Europe, presentation with ACS and diabetes were independent predictors of ST at one center, whereas no independent predictors of ST were identified from the other center. 4 The present large-scale, multicenter, international study, which included independent monitoring of all events and blinded adjudication of ST by an independent clinical events committee, adds clarity to the predictors of early and late ST in a moderate and high-risk NSTE-ACS population.
In the present study, the independent clinical determinates of ST were insulin-treated diabetes, ST-segment deviation Ն1 mm, and the number of diseased vessels. When detailed angiographic parameters were added to the multivariable model, the most important predictor of definite ST was the extent of coronary artery disease; insulin-treated diabetes was the only clinical variable that remained predictive. These findings underscore the importance of considering the burden of atherosclerotic disease when considering the risk of ST and suggest that the association of selected clinical risk factors with ST in prior studies may be explained by their correlation with more extensive atherosclerosis. Of note, some intraprocedural events, such as thrombosis, abrupt closure, and no reflow, were significantly more frequent in patients with ST by univariable analysis, but they were not independent predictors of definite ST by multivariable analysis.
Some previous studies have called into question DES safety, suggesting that they may be associated with increased rates of late ST as compared with BMS. 25, 26 Although a subsequent meta-analysis of the randomized, double-blind trials comparing DES with BMS showed no difference 15 or a small excess of only very late ST (Ն1 year) with DES compared with BMS, 16 these studies enrolled mostly patients with stable coronary artery disease. The present study is the first large-scale investigation to investigate the relative risk of ST of DES versus BMS in NSTE-ACS patients. The rate of definite and definite/probable ST did not significantly differ between patients with DES versus those with BMS in either the early, late, or 1-year cumulative time periods.
This study has several limitations. Because it is a post hoc analysis, the results should be considered hypothesisgenerating. The angiographic analysis was restricted to the cohort of patients formally enrolled in the ACUITY angiographic substudy, a smaller subset (nϭ3405) than the entire stented population. Even though this cohort was still larger than most prior studies, only 69 patients had ST within 1 year (compared with 136 patients in the entire study population). Thus, the angiographic cohort may not have been large enough for complementary clinical correlates of ST to emerge as significant. Data regarding the exact timing of and reasons for aspirin and thienopyridine discontinuation were not consistently captured during follow-up, and therefore we could not fully assess the impact of dual antiplatelet therapy adherence on the risk of ST. We also did not collect data on clopidogrel hyporesponsiveness, the occurrence of which has been correlated with an increased risk of ST. 27 Because intravascular ultrasound examination was not routinely performed, we could not investigate the relationship between stent expansion, malapposition, residual disease, and dissection to ST. 28 Our study was also unable to directly explore other possible causes of ST, including delayed healing of the vessel wall, polymer hypersensitivity, strut fractures, and new plaque rupture within the stent site. 29 -31 In this regard, multivariable models can only demonstrate strong associations and not prove causality. Choice of stent was not randomized in ACUITY, and a high proportion of DES compared with BMS was used, especially in the United States-based angiographic substudy. Moreover, only the first-generation sirolimus-eluting and paclitaxel-eluting stents were used in this trial; recent experimental and clinical data suggest that newer DES, especially everolimus-eluting stents, may have reduced ST rates. 32 Clopidogrel and ticlopidine were the only thienopyridine agents used in ACUITY; recent randomized controlled trials have demonstrated that the more potent platelet ADP receptor antagonists prasugrel and ticagrelor reduce ST rates in patients with ACS. 33, 34 Procedural details including stent diameter and implantation pressure were not systematically collected in ACUITY, and therefore we could not investigate their impact on stent thrombosis.
In conclusion, early and late ST in patients with moderate and high-risk NSTE-ACS is not infrequent, occurring more commonly than after stent implantation in stable coronary artery disease. However, ST rates in NSTE-ACS are not increased with first generation DES compared with BMS use, nor by the use of bivalirudin monotherapy compared with a GPI-based regimen. Rather, the most important correlates of ST occurring within 1 year in NSTE-ACS are insulin-treated diabetes mellitus, ST-segment deviation Ն1 mm, and the number of diseased vessels (or the extent of coronary artery disease). Finally, ST in NSTE-ACS is associated with a markedly higher risk of mortality and major ischemic events, regardless of whether it occurs early or late after stent implantation.
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